Sign up for alerts
Want to make sure you never miss the latest updates?
Insights with impact
Industry Insight
Test insight post – do not send
Industry Insight
Test insight post – send
Industry Insight
The biology of roginolisib: Activity without immune toxicity
Industry Insight
End of year reflections from our CEO
Industry Insight
Driving breakthroughs for myelofibrosis care
Industry Insight
What’s next for cambritaxestat?
Industry Insight
Realizing the potential of PI3Kδ inhibitors in peripheral T-cell lymphomas
Industry Insight
iOnctura expands roginolisib trials to the US
Industry Insight
iOnctura enhances board to accelerate growth and innovation
Industry Insight
Addressing drug resistance in non-small cell lung cancer
Industry Insight
Scientific innovation in uveal melanoma
Industry Insight
Opportunities and challenges in oncology immunotherapy
Industry Insight
Reflections from our CEO
Industry Insight
Pancreatic cancer – our commitment to scientific advances
Industry Insight
A bold new era in global cancer drug discovery
Industry Insight
A note from our CEO
Industry Insight
Realising the potential of autotaxin therapy in cancer
Industry Insight
PI3Kδ inhibitors offer serious promise in solid tumors
Industry Insight
Emerging therapies offer hope for uveal melanoma patients
Download our corporate deck
Find out more about our mission to give patients more momets that matter
All news
Press coverage
Testing new taxonomy – do not send
Press release
Testing MailPoet on a back-dated article please ignore for the moment
Press release
Testing MailPoet on a back-dated article please ignore for the moment – Take 2
Data & publication
The PI3Kδ inhibitor roginolisib (IOA-244) preserves T-cell function and activity
Press release
iOnctura CEO to present at the 2026 J.P. Morgan Healthcare Conference
Press coverage
Drug Discovery World – Autotaxin inhibition: unlocking new frontiers in cancers and beyond
Data & publication
The selective PI3Kδ inhibitor roginolisib synergizes with ruxolitinib against progenitor cells from naïve and JAKi-refractory/resistant patients with myelofibrosis
Data & publication
Roginolisib (IOA-244), an orally bioavailable, selective PI3Kδ inhibitor, in combination with venetoclax and rituximab in patients with relapsed chronic lymphocytic leukemia (CLL)
Data & publication
PlaΤform: A multicenter, multi-arm, academic platform trial evaluating novel agents and combinations in relapsed or refractory peripheral T-cell lymphomas
Data & publication
Trial in progress: A study of roginolisib in combination with ruxolitinib in patients with myelofibrosis who are unresponsive to JAK inhibitors (HEMA-MED)
Press coverage
Drug Discovery World – ASH 2025: Combined focus on myelofibrosis
Press release
iOnctura initiates Phase I/II trial in patients with myelofibrosis ahead of new non-clinical data at ASH
Looking for media
resources?